Eight years after launching CellSearch to identify and count circulating tumor cells, Johnson & Johnson's Veridex LLC unit has new data showing the technology may have the potential to predict heart attacks. Additional testing will be required to figure out whether the findings can be developed into a test.

Veridex first launched CellSearch in 2004 to identify and count circulating tumor epithelial cells (CTCs) in blood samples from cancer patients. The in vitro diagnostic is approved to predict progression-free survival (PFS) and overall survival (OS) for patients with metastatic breast, colorectal and prostate cancers.